Back to Blog
Red pill 1 25/5/2023 ![]() ![]() For example, your “Formula 1 – Full Spectrum CBD,” “Gold CBD,” and “Crave CBD” products contain a Supplement Facts panel. It appears that you intend to market at least some of your CBD products as dietary supplements. You can find specific information about how FDA regulates CBD at. You can find the FD&C Act and FDA regulations through links on FDA’s home page at. As explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&C Act. 360b(a), and adulterated under section 501(a)(5) of the FD&C Act, 21 U.S.C. FDA has also determined that your “Red Pill CBD Pet” product is an unapproved new animal drug that is unsafe under section 512(a) of the FD&C Act, 21 U.S.C. Furthermore, these products are misbranded drugs under section 502(f)(1) of the FD&C Act, 21 U.S.C. Cream,” “Pain Relief CBD Bath Bombs,” “Gold,” “Balance,” “Pain Freeze Cream,” “Fit,” “Crave,” “Romance for Men,” “Romance for Women,” “Sleep,” “Relax,” “Focus,” and “Relief” products are unapproved new drugs sold in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), 21 U.S.C. 355(a) and 331(d). The claims on your websites and social media websites establish that your “Formula 1,” “Red Pill Nano I.P.R. We have also reviewed your social media websites at and these websites direct consumers to your website, to purchase your products. Cream,” “Pain Relief CBD Bath Bombs,” “Gold,” “Balance,” “Pain Freeze Cream,” “Fit,” “Crave,” “Romance for Men,” “Romance for Women,” “Sleep,” “Relax,” “Focus,” “Relief,” and “Pet,” all of which you promote as products containing cannabidiol (CBD). Food and Drug Administration (FDA) reviewed your websites at and in September and October 2019 and has determined that you take orders there for the products “Red Pill Formula 1,” “Red Pill Nano I.P.R. This letter is to advise you that the U.S. Issuing Office: Center for Food Safety and Applied Nutrition (CFSAN) ![]()
0 Comments
Read More
Leave a Reply. |